Shuttle Pharmaceuticals Commences Trading on Nasdaq Under Ticker Symbol “SHPH”

by B2i | Aug 31, 2022 | Press Releases

Shuttle Pharma's platform of sensitizers are designed to address the urgent clinical need to improve the outcomes of cancer patients treated with radiation therapy while reducing side effectsROCKVILLE, Md., Aug. 31, 2022 — Shuttle Pharmaceuticals Holdings,...

Shuttle Pharmaceuticals Announces Pricing of Initial Public Offering

by B2i | Aug 30, 2022 | Press Releases

ROCKVILLE, Md., Aug. 30, 2022 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing side...

Shuttle Pharma Awarded a New Patent for Selective Inhibitors for Cancer Treatment

by B2i | Jul 29, 2021 | Press Releases

ROCKVILLE, Md., July 29, 2021 — Shuttle Pharmaceuticals Holdings, Inc (Shuttle Pharma), a Maryland-based developer of new drugs for cancer treatment, was awarded US Patent No.: 11,034,667 B2 for “Selective Histone Deacetylase Inhibitors for the treatment...

Shuttle Pharmaceuticals Holdings, Inc. Announces Appointment of Chris Senanayake, PhD To Board of Directors

by B2i | May 20, 2021 | Press Releases

ROCKVILLE, Md., May 20, 2021 — Shuttle Pharmaceuticals Holdings, Inc., (Shuttle Pharma) a clinical stage company developing drugs to improve the treatment of cancer patients undergoing radiation therapy is pleased to announce the addition of Chris Senanayake,...

Shuttle Pharmaceuticals, Inc. Awarded a New Patent for Dual Function HDAC Molecules for HDAC Inhibition and Ataxia Telangiectasia Mutated Activation for Cancer Treatment

by B2i | Nov 4, 2020 | Press Releases

ROCKVILLE, Md., Nov. 4, 2020 — Shuttle Pharmaceuticals, Inc (Shuttle Pharma) a clinical stage, Maryland-based, biopharmaceutical company developing new drugs for cancer treatment in combination with radiation therapy, was awarded patent number 10,745,352 by the...